FDA approval of Breyanzi offers real hope to CLL and SLL patients!
I’ve got to say I’m very, very pleased for BMS for the 15-May-2024 FDA approval of their CAR-T drug Breyanzi for […]
Read MoreCancer
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia – A Randomized Clinical Trial
In newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), disease progression due to acquired resistance to first- or second-generation […]
Read MoreExcellent ADC review in lung and breast cancer to keep you up to date!
An excellent and very timely review published a week and a half ago on where we are now with ADCs […]
Read MoreODAC’s unanimous 12-0 vote to allow MRD as an accelerated approval endpoint for multiple myeloma is a triumph in the right direction!
The last 2 weeks has seen the oncology world reacting and responding to the phenomenon of Minimal Residual Disease or MRD. […]
Read MoreThe Antibody Drug Conjugate (ADC) stage just gets hotter and hotter!
Maybe I’m just a little biased, preoccupied and obsessed with ADCs but the last 2 weeks or so has seen […]
Read MoreProbiotics to the rescue!
Oral mucositis (OM) is a common debilitating toxicity associated with radiotherapy (RT) for malignant head and neck tumors. This prospective, […]
Read MoreExploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials
Immune checkpoint inhibitors (ICIs) have significantly improved the survival of patients with cancer and provided long-term durable benefit. However, ICI-treated […]
Read MoreImpact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis
The addition of pembrolizumab (pembro) to neoadjuvant chemotherapy (NAC) is standard of care for the treatment of early triple-negative breast […]
Read MoreThe neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
Lineage plasticity is a recognized hallmark of cancer progression that can shape therapy outcomes. The underlying cellular and molecular mechanisms […]
Read MoreDevelopment and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate […]
Read More